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Aims The LION-HEART study was a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial
evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients
with advanced chronic heart failure.
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Methods
and results
Sixty-nine patients from 12 centres were randomly assigned at a 2:1 ratio to levosimendan or placebo groups,
receiving treatment by a 6-hour intravenous infusion (0.2𝜇g/kg/min without bolus) every 2weeks for 12weeks. The
primary endpoint was the effect on serum concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP)
throughout the treatment period in comparison with placebo. Secondary endpoints included evaluation of safety,
clinical events and health-related quality of life (HRQoL). The area under the curve (AUC, pg.day/mL) of the levels
of NT-proBNP over time for patients who received levosimendan was significantly lower than for the placebo group
{344× 103 [95% confidence interval (CI) 283× 103−404× 103] vs. 535× 103 [443× 103−626× 103], P= 0.003}. In
comparison with the placebo group, the patients on levosimendan experienced a reduction in the rate of heart
failure hospitalisation (hazard ratio 0.25; 95% CI 0.11–0.56; P= 0.001). Patients on levosimendan were less likely to
experience a clinically significant decline in HRQoL over time (P= 0.022). Adverse event rates were similar in the
two treatment groups.
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Conclusions In this small pilot study, intermittent administration of levosimendan to ambulatory patients with advanced systolic
heart failure reduced plasma concentrations of NT-proBNP, worsening of HRQoL and hospitalisation for heart failure.
The efficacy and safety of this intervention should be confirmed in larger trials.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Heart failure (HF) is a progressive condition with a highly negative
impact on the health care systems, and advanced HF represents a
segment of patients with higher risk of death and hospitalisation
and poorer health-related quality of life (HRQoL).1–3 Advanced
HF is defined by the presence of objective evidence of cardiac dys-
function, poor functional capacity, recurrent episodes of systemic
and/or pulmonary congestion that translate into recurrent hos-
pitalisations, impaired HRQoL and persistence of these features
despite attempts to optimise therapy.3
Beyond the guideline-recommended drug and device ther-
apy, specific therapeutic options are limited and quite often
fail to slow disease progression in many of these patients. The
more complex advanced therapies such as long-term mechani-
cal circulatory support and/or heart transplant (HTx) are only
available for a very limited number of patients with advanced HF.
Thus, new therapeutic approaches capable of slowing down or
preventing clinical progression and avoiding hospitalisation are
an unmet need.3,4
The use of repetitive or continuous infusions of inotropic drugs
to provide periods of intermittent haemodynamic relief in patients
with advanced HF has been associated with improvements in symp-
toms and has been considered an attractive approach.4 However,
data from several studies and meta-analyses of randomised trials
evaluating the safety and efficacy of beta-adrenergic agonists and
phosphodiesterase inhibitors in patients with HF suggest that this
approach might not be safe.5
In contrast with other inotropes, the inodilator levosimendan
promotes sensitization of the contractile apparatus to calcium
ions without increasing the levels of intracellular calcium.6 Lev-
osimendan has additional effects, mediated by its effect on the
ATP-dependent potassium channel at the vascular level, pro-
moting vasodilatation, and at the mitochondrial level, promoting
cardioprotection.6,7 Due to the pharmacological properties
of levosimendan, its long-lasting derived metabolites and its
positive haemodynamic and cardioprotective effects, a pulsed
or intermittent use of levosimendan has been suggested by
some authors as an interesting therapeutic strategy in patients
with advanced HF.7,8
Previous trials testing this strategy have been mostly open-label,
uncontrolled or single-centre studies,8 and well-designed ran-
domised controlled trials have shown neutral results.9,10 Therefore,
there are still uncertainties regarding the efficacy and safety of inter-
mittent infusions of levosimendan and their potential impact on the
outcomes in patients with advanced HF.
Thus, the aim of our study was to evaluate the clinical impact
of outpatient administration of intermittent intravenous infusions
of levosimendan in patients with advanced HF. In this study, the
primary endpoint of efficacy was the effect of ambulatory intra-
venous infusions of levosimendan compared to placebo, on the
serum concentrations of N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP) throughout the 12-week treatment period. Sec-
ondary endpoints included safety, patient-reported outcomes and
clinical events. ..
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The LION-HEART study (Levosimendan® Intermittent administra-
tion in Outpatients: effects on Natriuretic peptides in advanced
chronic HEART failure) was a multicentre, double-blind, randomised,
parallel-group, placebo-controlled trial evaluating the efficacy and safety
of intravenous administration of intermittent doses of levosimendan in
outpatients with advanced chronic HF.
Study design and oversight
Between November 2010 and December 2012, 69 patients fulfilling
the inclusion criteria were enrolled from 12 recruiting centres in Spain
(Figure 1 and Section H of the online supplementary Appendix). The
study protocol was approved by the institutional review boards of each
participating centre and conducted in accordance with the principles
of the Declaration of Helsinki, International Conference on Harmo-
nization Good Clinical Practice, and local and national regulations. All
enrolled patients had provided written informed consent before any
study-related procedure was undertaken. Information on study inves-
tigators, committee members, registration and monitoring of the study
is provided in Sections A–C of the online supplementary Appendix.
Study population, eligibility
and recruitment
The study protocol and design are summarised in the supplemen-
tary material online, Figure S1. The main inclusion criteria were:
age> 18 years, left ventricular ejection fraction <35% (measured in
the previous 6months) and clinical diagnosis of advanced chronic HF.3
A more detailed description of the study design, inclusion and exclu-
sion criteria are provided in Section D of the online supplementary
Appendix.
Randomisation, blinding and therapy
Eligible patients were randomised at a 2:1 ratio to receive either
levosimendan or placebo. The placebo had the same appearance as
levosimendan to ensure that the treatment was concealed from both
the investigators and the study patients. Levosimendan or placebo
was administered every 2weeks by a 6-hour intravenous infusion
(0.2𝜇g/kg/min, without bolus) for 12weeks (6 cycles) in an ambulatory
administration setting that allowed non-invasive monitoring of vital
signs. All measurements were taken prior to the infusion (pre-infusion)
and 24 hours after initiation if the infusion (post-infusion). Additional
key data on randomisation and therapy are provided in Section E of the
online supplementary Appendix.
Data collection and evaluation of the
efficacy and safety endpoints
Baseline information was obtained for stable patients, including the
relevant clinical and demographic information. All the data including
clinical events was re-evaluated every 2weeks for the first 3months
and every 4weeks during the next 3months.
The primary endpoint of efficacy in the LION-HEART study was
the effect of 6 cycles of ambulatory 6-hour intravenous infusions
of levosimendan every 2weeks on the serum concentrations of
NT-proBNP throughout the 12-week treatment period, in comparison
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Figure 1 Flow chart of screening, randomisation and follow-up of the study.
with placebo. Measurements of NT-proBNP levels were performed
locally using an immunoassay based on chemiluminescence, employ-
ing the Elecsys® System (Roche Diagnostics, Rotkreuz, Switzerland).
This method was used in all centres.
Key secondary safety and efficacy objectives comprised functional
variables, patient-reported outcomes and clinical events including hos-
pitalisation, death and other terminal events such as HTx and left ven-
tricular assist device (LVAD) implant. Additional information on clinical
data collection and other key aspects of safety and efficacy data are
summarised in Section F of the online supplementary Appendix.
Statistical analyses
Data analysis was performed following an intention-to-treat strategy.
For the primary efficacy analysis, a comparison of the area under ..
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. the curve (AUC) of the NT-proBNP values (expressed as pg.day/mL)
throughout the treatment period (from the baseline visit 1 to visit 7 at
week 12) and the pre–post mean treatment difference was conducted,
according to treatment allocation and taking into account patients who
had died or were hospitalised at that time. Treatment groups were
compared with respect to these primary endpoints using ANCOVA
adjusted for baseline measurements and ANOVA, respectively.
Repeated measures ANCOVA adjusted for baseline was used to
compare treatment groups with respect to follow-up NT-proBNP
values; the treatment-by-time interaction was examined in a sensitivity
analysis. ANCOVA adjusted for baseline was also used to evaluate
relative changes in NT-proBNP from baseline to the end of the
treatment period at week 12.
Missing NT-proBNP values were imputed using last observation
carried forward for patients who were known to be alive and not
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hospitalised for that specific period. If a patient was hospitalised or
had a terminal event, the highest preceding NT-proBNP value for this
particular patient was imputed.
For the secondary efficacy and safety analyses, differences between
treatments in the rate of occurrence of clinical endpoints were tested
using Cox proportional hazards regression; hazard ratios (HR) and
associated 95% confidence intervals (CI) estimated from the models
are presented. Kaplan–Meier survival curves comparing time to the
first event by means of a log-rank test for the composite event of
all-cause death or HF hospitalisation between both groups were also
generated.
The cumulative risk of HF hospitalisation taking all-cause death into
account as a competing risk was assessed using a Fine–Gray extension
of the Cox regression model implemented in the cmprsk R package.11
Changes in continuous outcomes representing secondary efficacy and
safety endpoints were analysed using repeated measures ANCOVA
adjusted for baseline measurements.
Additional information on statistical aspects of the study is provided
in Section G of the online supplementary Appendix.
All statistical tests and CI were constructed with a type I error level
of 5% with no adjustments for multiplicity, and a P-value of ≤0.05 was
considered statistically significant. SPSS version 18.0 (IBM, Armonk,
NY, USA) and the R software version 3.0.1 (R Foundation for Statistical
Computing, Vienna, Austria) were used for statistical analyses.
Results
Baseline characteristics
Baseline data of the patients are summarised in Table 1. Overall, 69
patients (48 receiving levosimendan and 21 placebo) were included
in the study. Both groups were well balanced for most demo-
graphic data and clinical characteristics. However, the patients in
the levosimendan group were older than in the placebo group
[median (interquartile range) 70 (63–75) years vs. 66 (57–68)
years, P= 0.025] and tended to have better renal function than
placebo patients [median (interquartile range) estimated glomeru-
lar filtration rate 55 (45–79) mL/min/1.73m2 vs. 51 (43–56)
mL/min/1.73m2, P= 0.095].
Administration of the study drug
The number of patients who received each scheduled cycle is
shown in Figure 1. A total of 61 patients (88%) received all
the scheduled drug infusions. Cumulative mean levosimendan
dose per patient was 30.3± 8.9mg [median: 31.5mg (Q25 –Q75:
27.2–35.3)].
Primary outcome
Primary endpoint analysis was performed evaluating 828 possi-
ble NT-proBNP measurements. Among these, only 26 (3.1%)
measurements were imputed. The baseline-adjusted AUC of
NT-proBNP levels (in pg.day/mL) over time was significantly
smaller in patients treated with levosimendan than in the
placebo group [344× 103, 95% CI 283× 103 –404× 103 vs.
535×103, 95% CI 443×103 –626×103; P= 0.003) (Figure 2A).
When more stringent imputation rules were applied to missing ..
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.. Table 1 Demographics and baseline characteristics of
the overall study population according to treatment
group
Variables Levosimendan (n= 48) Placebo (n= 21)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 68± 10 63± 9
Female gender 7 (15) 5 (24)
BMI, kg/m2 27± 4 27± 5
Systolic blood pressure, mmHg 114±17 107±10
Heart rate, b.p.m. 73± 12 74± 13
NYHA functional class
III 46 (96) 19 (91)
IV 2 (4) 2 (9)
LVEF, % 27± 9 25± 6
Ischaemic cause of HF 29 (60) 13 (62)
Previous CV hospitalisation
(1 year)
38 (79) 18 (86)
Previous HF hospitalisation
(1 year)
34 (71) 14 (67)
Co-morbidities
Hypertension 32 (67) 13 (62)
Atrial fibrillation 17 (35) 5 (24)
Diabetes mellitus 24(50) 11 (52)
Dyslipidaemia 27 (56) 14 (67)
Anaemia 29 (66) 12 (60)
Functional and PRO evaluation
6MWT distance, m 284± 95 299± 86
KCCQ overall summary
score
47± 22 47± 22
EQ-5D VAS score 49± 19 50± 14
Treatment
ACEIs or ARBs 37 (77) 12 (57)
Beta-blockers 37 (77) 19 (91)
MRAs 41 (85) 19 (91)
Digoxin 21 (44) 11 (52)
Diuretics 47 (98) 21 (100)
Hydralazine–nitrate
combination
2 (4) 1 (5)
Antiplatelet
therapy/anticoagulant
18 (38) 10 (48)
ICD 29 (60) 15 (71)
CRT 13 (27) 5 (24)
Laboratory measurements
Haemoglobin, g/dL 12.1± 2.3 12.8± 1.6
Serum creatinine, mg/dL 1.3± 0.4 1.4± 0.3
Serum creatinine, mg/dL 1.3 [1.0–1.4] 1.4 [1.2–1.6]
eGFR, mL/min/1.73m2 59± 21 49± 11
Na, mEq/L 137± 5 136± 4
K, mEq/L 4.3± 0.5 4.4± 0.6
NT-proBNP, pg/mL 5678± 4847 5419± 5331
NT-proBNP, pg/mL 4210 [2744–7095] 2770 [1736–7717]
Data are expressed as mean± standard deviation, as number (percentage), or as median
[interquartile range].
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body
mass index; CRT, cardiac resynchronisation therapy; CV, cardiovascular; eGFR, estimated
glomerular filtration rate; EQ-5D VAS, visual analogue scale of the Euro Quality of Life
5-dimension instrument; ICD, implantable cardioverter-defibrillator; K, potassium; KCCQ,
Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; 6MWT,
6-minute walking test; MRA, mineralocorticoid receptor antagonist; Na, sodium; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PRO,
patient-reported outcome.
assessments following terminal events, such as assigning the high-
est observed change from baseline over all patients for every
missing assessment following a terminal event, similar results were
observed.
The results based on AUC using log-transformed values were
also significant (P= 0.0185). The exclusion of one extreme value
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Figure 2 (A) Baseline-adjusted mean N-terminal pro-B-type
natriuretic peptide (NT-proBNP) levels (pg/mL) and associated
95% confidence intervals (CI) by visit and treatment group. Com-
parison of the baseline-adjusted area under the curve (AUC,
in pg.day/mL) of NT-proBNP levels by treatment group using
ANCOVA test. Comparison of baseline-adjusted NT-proBNP
(pg/mL) pre–post differences by treatment group using
ANOVA test: pre–post mean difference placebo= 1320 pg/mL
(95% CI 140; 2500); pre–post mean difference levosimen-
dan= –1446 pg/mL (95% CI –222; –666) (P< 0.001). (B)
Baseline-adjusted relative (percentage) change in NT-proBNP
from baseline to the end of treatment, by treatment group
[marginal means ± standard error of the mean (SEM)].
at visit 4 (week 7 of the study, 42 days after the first cycle) also
yielded significant results (P= 0.0018). Furthermore, the unad-
justed reduction in the NT-proBNP levels from baseline to the end
of treatment at week 12 was significantly greater in the levosimen-
dan group than in the placebo group (P= 0.007) (Figure 2A).
Analysis of repeated follow-up NT-proBNP values adjusted
for baseline NT-proBNP showed a significantly lower mean
NT-proBNP in the levosimendan group over the follow-up period
(P= 0.004).
The addition of a treatment-by-time interaction to the model
was statistically significant (P< 0.0001), consistent with a slight ..
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.. mean increase over time in the placebo group and a mean decrease
in the levosimendan group (Figure 2A).
The baseline-adjusted mean change in NT-proBNP from baseline
to week 12 was 1320 (95% CI 140–2500) pg/mL in the placebo
group and –1446 (95% CI –222; –666) pg/mL in the levosimendan
group (P< 0.001).
Analyses with ANCOVA tests, when individual NT-proBNP
data were log-transformed, showed similar results (P< 0.001). In
sensitivity analyses of the primary endpoint including age and renal
function as covariates, the results were consistent with the original
models.
The proportion of patients experiencing a clinically relevant
reduction in NT-proBNP levels (>25% from the baseline value)
was significantly higher (P= 0.002, Fisher’s exact test) in the lev-
osimendan (48%) than in the placebo group (9%). Due to the low
number of observations, we have included the P-values obtained
with the Fisher’s exact test. The mean percentage reduction in
NT-proBNP levels was also significantly greater in the levosimen-
dan group (P< 0.001) (Figure 2B).
Secondary outcomes
The distribution of clinical events according to treatment allocation
is shown in Table 2. During the study, 15 patients (31%) in the lev-
osimendan group and 8 patients (38%) in the placebo group died
(P= 0.781). In the placebo group, two patients underwent HTx,
and one received an LVAD implant, while this did not occur in
the levosimendan group (P= 0.025). The rate of all terminal events
(HTx, LVAD implant or death) was 48% (n= 10) in the placebo
group and 31% (n=15) in the levosimendan group (P= 0.303). The
patients experienced 64 hospitalisations for any cause, 44 cardio-
vascular (CV) hospitalisations and 37 HF hospitalisations. Patients
assigned to levosimendan experienced a significant reduction in the
rate of HF hospitalisation (HR 0.25, 95% CI 0.11–0.56; P= 0.001)
in comparison with the patients assigned to placebo (Table 2). The
improvement in HF hospitalisation rate also translated into a signif-
icant reduction in CV hospitalisation, all-cause hospitalisation and
the composite endpoints between hospitalisation (all-cause, CV or
HF) and death or other terminal events (Table 2 and Figure 3). We
also performed a competing-risks regression analysis of HF hos-
pitalisation, considering all-cause death a competing event. In this
analysis, and in agreement with the original results, levosimendan
was associated with a significant reduction in the risk of HF hos-
pitalisation throughout the study in comparison with placebo (HR
0.40, 95% CI 0.199–0.822; P= 0.012).
Analysis of safety and tolerability is shown in Table 3 and in
the online supplementary Table S1. Adverse events (AE) and seri-
ous adverse events (SAE) occurred in 57 (83%) and 51 (74%) of
patients, respectively. However, drug-related AE were observed
only in 7 patients (10%). There were no significant differences
between the assignment groups in terms of SAE, non-serious AE
or drug-related AE. Interestingly, drug-related SAE or AE leading
to study drug withdrawal tended to be lower in the levosimendan
group. The rate of patients needing an interim or permanent with-
drawal of drug infusions did not differ between the two groups.
The proportion of patients needing reduction or discontinuation
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Table 2 Clinical secondary pre-specified endpoints according to treatment group
Levosimendan (n= 48) Placebo (n= 21) P-value* Hazard ratio
(95% CI)
P-value†
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total
events
Patients
with at
least one
event, n (%)
Incidence
per 100
patient-
years
at risk
Total
events
Patients
with at
least
one event,
n (%)
Incidence
per 100
patient-
years
at risk
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Death or other terminal events
All-cause death 15 15 (31.2) 31.3 8 8 (38.1) 38.1 0.781 0.80 (0.34–1.90) 0.620
HTx 0 0 (0) 0.0 2 2 (9.5) 9.5 0.090 – –
LVAD implant 0 0 (0) 0.0 1 1 (4.8) 4.8 0.304 – –
Hospitalisation
HF hospitalisation 19 11 (22.9) 22.9 18 14 (66.7) 66.7 0.001 0.25 (0.11–0.56) 0.001
CV hospitalisation 21 12 (25.0) 25.0 23 14 (66.7) 66.7 0.003 0.27 (0.12–0.59) 0.001
Non-CV hospitalisation 15 9 (18.8) 18.8 5 4 (19.0) 19.0 0.999 1.01 (0.31–3.27) 0.990
All-cause hospitalisation 36 17 (35.4) 35.4 28 15 (71.4) 71.4 0.012 0.37 (0.19–0.75) 0.006
Composite endpoints
HF hospitalisation or all-cause death 34 22 (45.8) 29.2 26 17 (81.0) 66.7 0.015 0.33 (0.16–0.70) 0.004
CV hospitalisation or all-cause death 36 22 (45.8) 39.6 31 17 (81.0) 81.0 0.015 0.32 (0.16–0.61) 0.001
All-cause hospitalisation or all- cause death 51 25 (52.1) 45.8 36 18 (85.7) 85.7 0.017 0.38 (0.20–0.71) 0.003
HTx or LVAD implant 0 0 (0) 0.0 3 3 (14.3) 14.3 0.025 – –
HTx or LVAD or death 15 15 (31.2) 31.3 11 10 (47.6) 47.6 0.303 0.55 (0.25–1.22) 0.143
HF hospitalisation or HTx or LVAD 19 11 (22.9) 22.9 21 14 (66.7) 66.7 0.001 0.25 (0.11–0.55) 0.001
HF hospitalisation or HTx or LVADor death 34 22 (45.8) 41.7 29 17 (81.0) 81.0 0.015 0.34 (0.17–0.65) 0.001
CV hospitalisation or HTx or LVAD 21 12 (25.0) 25.0 25 14 (66.7) 66.7 0.003 0.27 (0.12–0.58) 0.001
CV hospitalisation or HTx or LVADor death 36 22 (45.8) 41.7 33 17 (81.0) 81.0 0.015 0.33 (0.17–0.63) 0.001
CI, confidence interval; CV, cardiovascular; HF, heart failure; HTx, heart transplant; LVAD, left ventricular assist device.
Comparison between both groups using *Kaplan–Meier (P-value corresponds to a log-rank test) and †Cox regression methods.
Figure 3 Kaplan–Meier survival curves (time to the first event)
for the composite event of all-cause death or heart failure
hospitalisation. P-value according to log-rank test.
of the infusion due to significant arterial hypotension (<80mmHg
or <100mmHg with symptoms) was larger in the levosimendan
than in the placebo group, but there were no statistically sig-
nificant differences (Table 3 and online supplementary Figure S2).
The ANCOVA tests for repeated measures, adjusted for baseline
measurements, showed no significant difference in systolic blood
pressure values between the two groups during the treatment ..
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. period (P= 0.314; online supplementary Figure S3). Feasibility of
drug administration is shown in the supplementary online Table S2.
The number of patients who received the 6 cycles of treatment was
significantly higher (P= 0.044) in the levosimendan (45 patients,
94%) than in the placebo group (16 patients, 76%).
No differences were observed in heart rhythm parameters and
rhythm disturbances between the two groups during the first cycle
of administration of the study drug. In this period, new-onset atrial
fibrillations were not observed. Changes in the parameters of renal
(estimated glomerular filtration rate, P= 0.226) and liver func-
tions (alanine and aspartate transaminases, P= 0.583 and P= 0.202,
respectively) were similar in the two groups.
For the patient-centred outcomes, adjusted analyses with the
imputation of missing data did not show significant changes in New
York Heart Association (NYHA) class (P= 0.841) or in EQ-5D
visual analogue scale (VAS) scores (P= 0.474) in the two groups
throughout the study. However, in analyses without imputation and
after 6months of follow-up, the patients on levosimendan were
more likely to improve by at least one NYHA class (odds ratio
4.3, 95% CI 1.1–18.3; P= 0.042). They also were less likely to
experience a clinically significant decline in HRQoL according to
EQ-5D VAS [5/24 levosimendan patients (21%) vs. 7/11 placebo
patients (63%), P= 0.022] (Figure 4).
Discussion
In the LION-HEART study, treatment of 6 cycles of intermit-
tent infusions of levosimendan administered to outpatients with
advanced chronic HF significantly reduced NT-proBNP levels
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Table 3 Description of adverse events and tolerability according to treatment group
Levosimendan (n= 48) Placebo (n= 21) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Safety, n (%)
Any AE 37 (77.1) 20 (90.9) 0.204
SAE 32 (66.7) 19 (86.4) 0.152
Drug-related AE 5 (10.4) 2 (9.1) 0.999
Drug-related SAE 3 (6.2) 2 (9.1) 0.646
AE leading to drug withdrawal 2 (4.2) 4 (18.2) 0.073
Tolerability, n (%)
Temporary discontinuation of infusion 1 (2.1) 0 (0.0) 0.999
Permanent discontinuation of infusion 5 (10.4) 3 (14.3) 0.692
Reduction or discontinuation due to arterial hypotensiona 7 (14.9) 2 (9.5) 0.712
AE, adverse event; SAE, serious adverse event.
aSystolic blood pressure< 80mmHg or <100mmHg with symptoms.
Figure 4 Proportion of patients reporting a clinically signifi-
cant decline in their self-reported quality of life at 6months of
follow-up, according to treatment group. A clinically significant
decline was considered a reduction of 5 points (minimal clini-
cally important difference) on the EQ-5D visual analogue scale
between the baseline and visit 10 (6months).
(primary endpoint of the study) in comparison with placebo. This
positive effect translated into clinical improvements: compared
to the placebo group, the levosimendan patients experienced a
significant reduction in the risk of hospitalisation, mainly driven
by a significant reduction in HF-related hospitalisations. Moreover,
the composite endpoints including hospitalisation (all-cause, CV
or HF) and death or other terminal events were also significantly
lower in the levosimendan group. Consistently with these findings,
a significant decline in HRQoL over time was more common in
placebo patients. Importantly, the safety and tolerability of lev-
osimendan were similar to those of placebo. Although beneficial
clinical effects of intermittent use of levosimendan in advanced HF
have been previously suggested,8–10 our study is the first multi-
centre trial showing positive results in both primary (decrease in
natriuretic peptide levels) and key secondary endpoints such as
hospitalisation.
These results could be explained by the haemodynamic
and cardioprotective effects of levosimendan,6,7 which might
improve left ventricular performance without increasing oxygen
consumption.12 We could hypothesise that intermittent exposure ..
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.. to levosimendan provided short periods of haemodynamic
relief. This might have caused a reduction in natriuretic peptide
concentration and a decrease in the number of clinical events.
Since previous studies have shown that 6-hour infusions of a similar
dose of levosimendan do not sustain the haemodynamic effect
after 2weeks,13 the intermittent episodes of haemodynamic relief
cannot be the only explanation of our results. However, we might
also hypothesise that an intermittent exposure to levosimendan
slows the progression of the disease due to its cardioprotective
effects. One might speculate that the preservation of cardiac
function prevents new episodes of haemodynamic deterioration.
This, in turn, would translate into a reduction in the number of
HF-related events and a relative preservation of HRQoL.14,15
Despite some similarities between our study and the LevoRep
study, the latter has failed to demonstrate a positive effect for its
primary endpoint, although a positive trend for secondary clinical
endpoints was reported.9 Several aspects related to the LevoRep
study design might explain the differences between these two
studies. In particular, the number of treatment cycles was larger
in the LION-HEART study (6 cycles) than in the LevoRep study
(4 cycles). This resulted in a two-fold increase in the mean cumula-
tive dose of levosimendan per patient in our study (30.3± 8.9mg)
in comparison with the LevoRep results (14.3± 4.7mg). The
use of NT-proBNP as the primary endpoint in our study was
sustained by two main reasons. Firstly, natriuretic peptide levels
are correlated with the haemodynamic status of the patients,16 and
the changes in their levels mimic the changes in the overall cardiac
performance in response to therapeutic interventions. For this
reason, the changes in NT-proBNP levels have also been used as
primary endpoints in other studies.17 However, this biomarker has
been reported as an imperfect surrogate of clinical events.18 Sec-
ondly, the LION-HEART trial was designed as a proof-of-concept
study: we were testing the use of levosimendan with a dose,
duration of infusion, interval between infusions and clinical setting
(outpatients with advanced HF) that had not been tested before.
Thus, demonstrating the proof-of-concept that this administration
scheme would translate into a measurable biological effect was a
key aspect of the study. In this regard, the evaluation of changes
in the NT-proBNP levels throughout the treatment using an AUC
© 2018 The Authors
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approach helped to define the biological impact of this therapeutic
strategy (mitigation of the neurohormonal burden imposed by
advanced HF) and correlate these changes with improved clinical
outcomes.
An additional important message of our study is that the admin-
istration of levosimendan following the regime proposed in the
LION-HEART is safe and well tolerated. No differences were found
in adverse event rates, both serious and non-serious, between
the levosimendan and placebo groups. The proportion of deaths
tended to be lower for the patients allocated to levosimendan than
in the placebo group (31% vs. 38%), although this trend was not sta-
tistically significant. This is in contrast with other studies of acute
HF, where the administration of levosimendan was associated with
a non-significant increase in the number of fatal events in compar-
ison with placebo.18,19 Excessive hypotension associated with the
use of bolus of levosimendan might explain this difference.
The treatment was well tolerated and, in fact, the proportion
of patients that received the 6 cycles of treatment tended to be
higher in the levosimendan group. Importantly, there were no
differences between the percentages of patients in the two groups
needing an interruption in the infusion procedure due to significant
hypotension. A similar level of safety and tolerability has been
reported in the LevoRep study.9 Based on that, the repetitive
6-hour outpatient infusions of levosimendan in advanced HF seem
to be a feasible approach. This is very important considering the
limited available therapeutic options for such patients.
Study limitations
The LION-HEART study was powered to evaluate the differ-
ences in NT-proBNP levels between the two allocation groups
over the treatment period. However, our study was not pow-
ered to evaluate the differences in clinical events, symptoms and
patient-reported outcomes. Given the calculated sample size, all
these evaluations were planned as exploratory. However, the find-
ings for these secondary endpoints were consistent with the results
for the primary endpoint and were statistically significant despite
the limited sample size. Although there were no safety signals, a
much larger, adequately powered study is needed to ensure that
levosimendan does not cause more hypotension, arrhythmias and
mortality than the placebo and to confirm its effects on the clinical
outcomes observed in the LION-HEART study.
Conclusions
This exploratory pilot study demonstrated that an intermittent
administration of levosimendan to ambulatory patients with
advanced systolic HF was safe, significantly decreased the level
of natriuretic peptides and was associated with clinical benefits.
Larger studies are needed to confirm the safety and efficacy of this
therapeutic strategy and its effect on clinical and patient-reported
outcomes.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article. ..
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.. Appendix. Supplementary material.
Table S1. Description of serious and non-serious adverse events
following the MedRA classification and according to treatment.
Table S2. Analysis of the feasibility and heart rhythm safety of the
study drug administration.
Figure S1. Diagram summarizing the study protocol and design.
Figure S2. Percentage of patients in the two treatment groups
needing a reduction or interruption of treatment due to significant
hypotension (defined as systolic blood pressure< 80mmHg or
<100mmHg associated with symptoms).
Figure S3. Comparison of systolic blood pressure values and 95%
confidence interval by visit and treatment group using ANCOVA
for repeated measures.
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